Skip to main content

Table 2 Pulmonary function and laboratory data before and after NTB treatment

From: Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study

Pulmonary function data / Laboratory data

Total

(n = 26)

NTB group (n = 15)

NTB + IS group

(n = 11)

p

At the start of NTB treatment

VC (vital capacity)

% of predicted value, %

64.8 ± 17.0

65.8 ± 18.8

63.4 ± 14.9

0.876

mean value, mL

1,860.4 ± 709.2

1,965.3 ± 816.3

1,717.3 ± 534.5

0.378

FVC (forced vital capacity)

% of predicted value, %

62.5 ± 16.7

64.3 ± 18.7

60.1 ± 14.0

0.586

FEV1/FVC (forced expiratory volume in 1 s divided by forced vital capacity)

mean value, %

89.4 ± 6.8

86.6 ± 6.7

93.2 ± 5.1

0.020*

DLCO (diffusing capacity for carbon monoxide) †

% of predicted value, %

48.1 ± 24.3 (n = 15)

56.4 ± 24.4 (n = 8)

38.7 ± 22.1 (n = 7)

0.272

DLCO/VA (diffusing capacity for carbon monoxide divided by alveolar volume) †

% of predicted value, %

71.9 ± 27.0 (n = 15)

76.6 ± 20.2 (n = 8)

66.6 ± 34.2 (n = 7)

0.524

Monthly change in FVC before NTB treatment§, %/month

−0.70 ± 0.56 (n = 18)

−0.46 ± 0.35 (n = 11)

−1.07 ± 0.65 (n = 7)

0.024*

KL-6, U/mL

1,240.1 ± 839.7

1,001.7 ± 661.5

1,565.2 ± 974.1

0.040*

After NTB treatment

Follow-up period since NTB was started, months

8.4 ± 2.3

8.1 ± 2.4

8.8 ± 2.0

0.351

VC (vital capacity)

% of predicted value, %

67.9 ± 18.5

64.0 ± 19.1

73.3 ± 17.1

0.276

mean value, mL

1,941.9 ± 760.4

1,908.0 ± 823.3

1,988.2 ± 701.7

0.917

FVC (forced vital capacity)

% of predicted value, %

67.0 ± 17.2

63.2 ± 17.6

72.3 ± 15.8

0.213

FEV1/FVC (forced expiratory volume in 1 s divided by forced vital capacity)

mean value, %

86.5 ± 9.5

84.5 ± 10.9

89.3 ± 6.6

0.213

DLCO (diffusing capacity for carbon monoxide) †

% of predicted value, %

46.0 ± 24.0 (n = 15)

50.6 ± 28.0 (n = 8)

40.7 ± 19.3 (n = 7)

0.643

DLCO/VA (diffusing capacity for carbon monoxide divided by alveolar volume) †

% of predicted value, %

68.4 ± 24.4 (n = 15)

69.3 ± 26.0 (n = 8)

67.3 ± 24.5 (n = 7)

0.772

Monthly change in FVC after NTB treatment§, %/month

+ 0.54 ± 1.56 (n = 18)

−0.17 ± 0.86 (n = 11)

+ 1.50 ± 1.81 (n = 7)

0.001**

KL-6, U/mL

964.4 ± 597.2

883.3 ± 518.7

1,075.1 ± 974.1

0.468

  1. Data are expressed as mean ± standard deviation (SD). NTB: nintedanib; IS: immunosuppressive agents; KL-6: Krebs von den Lungen-6
  2. † DLCO was measured in 15 of 26 patients
  3. § The monthly change in FVC (%/month) before and after NTB treatment was calculated for 18 of the 25 patients who underwent a pulmonary function test before NTB treatment (within 24 months before the start of NTB), at the start of NTB treatment (within 3 months before the start of NTB), and after NTB treatment (6–12 months after the start of NTB).
  4. For statistical analyses, *p < 0.05, **p < 0.01. P-value: Wilcoxon signed rank test, Fisher’s exact test
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us